Introduction

Rosuvastatin, the seventh drug in the statin class, is a synthetic and orally active inhibitor of HMG-CoA reductase used for the treatment of hypercholesterolemia. Early research indicated that rosuvastatin may achieve better outcomes than the other drugs in its class[1–6]. The pharmacokinetics of rosuvastatin were evaluated and reported previously. Both the maximum plasma concentration (C_{max}) and the area under the plasma concentration curve (AUC) are proportional to the dose[7–9]. Age, gender, smoking status, weight, body surface area, and lean body mass had no significant effect on rosuvastatin pharmacokinetics[10, 11]. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups[11]. Nevertheless, pharmacokinetic studies of rosuvastatin, including one conducted in North America, have demonstrated an approximate twofold elevation in median exposure (AUC and C_{max}) in Asian subjects compared with Caucasians[12, 13]. In dose-ranging studies, rosuvastatin produced dose-dependent mean reductions in LDL-C in both Western and Japanese hypercholesterolemia patients[1, 14]. Nevertheless, whether there are similar race differences in rosuvastatin pharmacodynamics is unknown because of a lack of clinical research directly comparing Western and Asian
patients. At present, considering the potential for increases in systemic exposure, it is recommended in the rosuvastatin product monograph that the dose range of rosuvastatin be 5 to 40 mg orally once a day, that the starting dose be 10 mg in Western patients and 5 mg in Asian patients, and that the maximum dose be 40 mg in Western patients and 20 mg in Asian patients[12]. Therefore, studies of the pharmacodynamics of rosuvastatin in Western and Asian patients are of clinical interest, and the results would improve clinical outcomes and optimize drug development.

This study attempted to pool the mean values of LDL-C reduction (%) from the eligible trials to develop a population pharmacodynamic (PPD) model for evaluating race differences in the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients.

**Materials and methods**

**Clinical studies included**

A comprehensive literature search in the Medline database was performed from January 1990 to June 2009, with the MeSH terms “rosuvastatin”, “hypercholesterolemia” and “clinical trials”. There were no language restrictions. Studies were eligible for inclusion if the following conditions were met: (1) the study was a randomized trial to investigate treatment with daily dosing of rosuvastatin in patients with hypercholesterolemia; (2) the percentage change in LDL-C from baseline was reported and the number of patients in each group was greater than 10; (3) the intervention duration was at least 4 weeks. Trials including statin-naive and switched-to-rosuvastatin patients were not eligible when they reported the pooled efficacy from only the two groups of patients. In addition, two Chinese clinical trials were available from our department. Of the eligible studies, the dose-ranging trials were used for model development and the one-dose trials were used for model prediction.

**Data extraction and data sets**

The mean percentage change in LDL-C from baseline, \( \text{IV} \), the primary efficacy endpoint, was extracted from each eligible study. In the case of a force-titrated trial, only the efficacy of the starting dose with intervention duration greater than 4 weeks was used in this investigation. Variables for which data were collected included intervention duration, baseline LDL-C, race (Western or Asian), and year of publication. The Western patients consisted predominantly of Whites/Caucasians and the Asian patients comprised Chinese, Japanese, and South Asian subjects.

**Population model construction**

Population pharmacodynamic analysis of rosuvastatin dose-response data was performed using the nonlinear mixed-effect modeling program NONMEM (Version V, Level 1.1; Globomax LLC, Hanover, MD, USA) and DAS version 3.0 (Bontz Inc, Beijing, China). A previously reported sigmoidal \( E_{\text{max}} \) model was used to characterize the dose-response relationship for rosuvastatin[15]:

\[
Y_{\text{obs}} = \frac{E_{\text{max}} \times \text{Dose}^\gamma}{ED_{50}^\gamma + \text{Dose}^\gamma} + E_0
\]

where \( E_{\text{max}} \) is the maximal drug effect, reflecting the maximal difference in response between placebo and rosuvastatin; \( \text{Dose} \) is the dose of rosuvastatin; \( ED_{50} \) is the drug dose associated with an effect equal to 50% of \( E_{\text{max}} \); and \( \gamma \) is the Hill coefficient reflecting the steepness of the dose-response curve. The term \( E_0 \) represents the placebo effect.

The following model structure was used for the PPD analysis:

\[
Y_{\text{obs}} = E + \eta + \varepsilon
\]

where \( Y_{\text{obs}} \) is the observed effect (the percentage change in LDL-C), \( \eta \) is a trial-specific random effect assumed to be normally distributed with a mean of 0 and an unknown variance of \( \omega^2 \), and \( \varepsilon \) is the residual error assumed to be normally distributed parameter with a mean of 0 and a variance of \( \sigma^2 \).

The model was established using the forward inclusion-backward elimination method[16, 17]. In the first step, the PPD analysis was conducted without any covariates in the basic model. In the second step, each candidate covariate (baseline LDL-C and race) was screened in turn by incorporating it into the basic model parameters to develop the intermediate and full models and by observing the decrease in the objective function value (OFV). Covariates were cumulatively added to the PPD model in a forward, stepwise manner in order of their contribution to the reduction in the OFV and until there was no further reduction in OFV. The difference in the OFV was maintained as a \( \chi^2 \) distribution, and an OFV greater than 3.84, associated with a \( P \) value of 0.05 (1 degree of freedom), was used for statistical significance. There were also many indicators of improved fit due to the addition of the following parameters to the model: decrease in standard error of the parameter estimates, reduction in intertrial variability, agreement between the observed and predicted effects, reduction in weighted residuals, and uniformity of the scatter plot of weighted residuals (WRES) versus predicted effects. Finally, a backward elimination step was performed by removing covariates one by one that already exited in the model. In the refinement of the PPD analysis, more stringent cutoff values were applied when determining whether to include a certain covariate or not. Covariates were retained in the model if their removal increased the OFV by 6.63, corresponding to a \( P \) value of 0.01 (1 degree of freedom).

Baseline LDL-C was included in the model as a continuous covariate. For the categorical covariate race (RACE), the covariate modeling was described by the following example:

\[
P = TVP \times 0^{\text{RACE}}
\]

where \( P \) is one of the pharmacodynamic parameters and \( TVP \) is the typical population parameter value of \( P \). The covariate RACE equals 0 for Westerners and 1 for Asians. If \( 0^{\text{RACE}} \) is significantly different from 1, it indicates that a race difference exists in the two populations.
Validation and prediction method

Model validation and prediction were used to test the robustness of the parameter estimates and the predictive capacity of the model. Validation of the PPD model was performed by the bootstrap method[18] and the data-splitting method[19]. The means of parameter estimates calculated from the 1000 bootstrap replications with successful runs (i.e., both the estimation and covariance steps successfully converged) were compared with the final parameter estimates obtained from the original data set. For the data-splitting method, data (subsets) were obtained by deleting one trial at a time in the full data set. Each subset was analyzed by NONMEM with the final model to obtain the parameter estimates, which were compared with those resulting from the full data set.

Monte Carlo simulations were performed 1000 times to predict the 50th percentile LDL-C reduction (as an estimator of the population predicted effect) and the 2.5th and 97.5th percentile LDL-C reductions. The predictive performance of the PPD model was evaluated by observing the mean effects with 95% intervals for Westerners and Asians.

Results

Data

The literature search yielded 93 trials (Figure 1). Of the 54 trials retrieved for detailed assessment, 20 were excluded: one because it focused on a special population (postmenopausal women receiving hormone replacement therapy), one because it included a small number of subjects, four because they included patients whose medications had been switched, five for duplicate reporting, and seven for lack of reduction in LDL-C outcomes. Therefore, 34 eligible studies were identified, 12 of which were dose-ranging trials (9 examined Westerners and 3 examined Asians)[1–3, 5, 14, 20–26] and 22 were one-dose trials (18 comprising Westerners and 4 comprising Asians)[27–48]. In addition to the eligible published studies, two eligible dose-ranging trials in Asians were available from our department. All 14 of the dose-ranging trials were randomized, parallel-group studies; among them, 12 were double-blind, three were placebo-controlled, and the majority were multicenter studies. Tables 1 and 2 summarize the Western and Asian dose-ranging trials. A total of 46 effect samples from the 14 dose-ranging trials were available for the development of the PPD model. A summary of the one-dose trials used for model prediction is presented in Table 3.

Population pharmacodynamics

In this study, the previously reported sigmoidal $E_{\text{max}}$ model described the dose-response relationship for rosuvastatin with incorrect pharmacodynamic parameters. Then, $\gamma$ was fixed at 1; that is, a simple $E_{\text{max}}$ model was used and the estimated parameters were acceptable except for a large relative standard error (RSE) in $E_0$. Therefore, $E_0$ was presumed to be -0.802% based on the literature value[15], and the simple $E_{\text{max}}$ model was used successfully as the basic model for subsequent covariate analysis. Only the covariate race on $E_{50}$ produced a small but significant decrease in the OFV (7.095). The resulting population model with the covariate $E_{50}$ was as follows:

$$E_{50}=1.74 \times 0.564^{\text{RACE}}$$

The PPD parameters in the final model are listed in Table 4. The RSE values for the parameters were acceptable, with a range from 3.86% to 28.55%. Figure 2 shows the fits of the observed effects with the parameters obtained from the final model. Figure 3 shows the final model-predicted dose-response curves for Westerners and Asians.

The goodness-of-fit plots for the final PPD model are presented in Figure 4. Generally, there was good agreement between observed (OBS) and population model-predicted (PRED) effects, as well as between OBS and individual model-predicted (IPRED) effects, with the magnitude of the WRES being small and randomly distributed over the entire range of PRED. Moreover, the goodness of fit to the model did not vary significantly among the trials.

Validation and prediction

Analysis of each of the 1000 bootstrap samples resulted in 928 samples that successfully converged. The mean values of the parameters after 928 repetitions of the bootstrap estimation were consistent with the parameter estimates of the original data set (Table 5), and the 95% CI was within reasonable...
The values of $E_{\text{max}}$, $ED_{50}$, and $\theta$ (race on $ED_{50}$) in the full data set and in the subsets are shown in Figure 5. The results indicated that the parameter values for subsets were within the range of the SE of the full data set estimates except for $\theta$ (race on $ED_{50}$) in subset 11.

The visual predictive check using Monte Carlo simulations showed the mean values of LDL-C reduction (%) from the one-dose trials were distributed, in most cases, within the 5th-to 95th-percentile boundaries of the dose-response profiles for both Westerners and Asians (Figure 6).

### Discussion

Rosuvastatin is widely used for the treatment of hypercholesterolemia and the recommended doses for Western and Asian patients are different because of a reported race difference in rosuvastatin pharmacokinetics. However, whether there are race differences in rosuvastatin pharmacodynamics remains unclear. In the absence of randomized, controlled studies directly comparing race differences in rosuvastatin pharmacodynamics, an indirect comparison through a model-based meta-analysis was used, characterizing the dose-response relationship for rosuvastatin in Western and Asian patients.

---

**Table 1.** Overview of Western dose-ranging trials for model building.

| Reference | Year | Duration (week) | Dose (mg) | No of patients | LDL-C baseline (mg/dL) | Reductions in LDL-C (%) |
|-----------|------|-----------------|-----------|----------------|------------------------|------------------------|
|           |      |                 |           |                |                        | Mean | SE     |
| 1         | 2001 | 6               | 0         | 29             | 197.2                  | 3.6 | 1.7   |
|           |      |                 | 1         | 13             | 189.4                  | 34.3| 2.6   |
|           |      |                 | 2.5       | 13             | 189.4                  | 40.7| 2.6   |
|           |      |                 | 5         | 17             | 193.4                  | 42.5| 2.4   |
|           |      |                 | 10        | 16             | 189.4                  | 50.5| 2.4   |
|           |      |                 | 20        | 13             | 181.7                  | 57  | 2.7   |
|           |      |                 | 40        | 34             | 185.6                  | 62.6| 1.5   |
|           |      |                 | 80        | 31             | 189.4                  | 64.8| 2     |
| 2         | 2001 | 12              | 5         | 119            | 190                    | 42  | 1.3   |
|           |      |                 | 10        | 111            | 186                    | 49  | 1.3   |
| 3         | 2002 | 12              | 5         | 135            | 188.0                  | 46  | 1.3   |
|           |      |                 | 10        | 132            | 185.9                  | 50  | 1.3   |
| 20        | 2002 | 12              | 0         | 132            | 187                    | 0   | 1.2   |
|           |      |                 | 5         | 128            | 188                    | 40  | 1.3   |
|           |      |                 | 10        | 129            | 185                    | 43  | 1.3   |
| 21        | 2002 | 12              | 5         | 121            | 187.3                  | 39.1| 1.3   |
|           |      |                 | 10        | 115            | 187.0                  | 47.4| 1.3   |
| 22        | 2003 | 6               | 5         | 38             | 193                    | 41.5| 1.4   |
|           |      |                 | 10        | 45             | 190                    | 46.6| 1.1   |
|           |      |                 | 20        | 38             | 188                    | 51.7| 0.9   |
|           |      |                 | 40        | 44             | 188                    | 56.8| 1.1   |
|           |      |                 | 80        | 42             | 198                    | 61.9| 1.4   |
| 5         | 2003 | 6               | 10        | 156            | 188                    | 45.8| 1.0   |
|           |      |                 | 20        | 160            | 187                    | 52.4| 1.1   |
|           |      |                 | 40        | 157            | 194                    | 55  | 1.1   |
| 23        | 2004 | 12              | 5         | 127            | 188                    | 39.8| 1.1   |
|           |      |                 | 10        | 128            | 186                    | 47.1| 1.1   |
| 24        | 2006 | 6               | 10        | 475            | 172                    | 45.8| 0.5   |
|           |      |                 | 20        | 478            | 173                    | 52.3| 0.5   |
|           |      |                 | 40        | 475            | 173                    | 56.7| 0.5   |

SE, standard error. Dose=0, placebo.
### Table 2. Summary of Asian dose-ranging trials for model building.

| Reference | Year | Duration (week) | Dose (mg) | No of patients | LDL-C baseline (mg/dL) | Reductions in LDL-C (%) Mean | SE |
|-----------|------|-----------------|-----------|----------------|------------------------|----------------------------|----|
| 25        | 2002 | 8               | 1         | 19             | 219.4                  | 30.0                       | 3.3 |
|           |      |                 | 2         | 16             | 217.8                  | 36.5                       | 2.2 |
|           |      |                 | 4         | 18             | 203.8                  | 41.5                       | 3.5 |
| 14        | 2003 | 6               | 0         | 12             | 190.0                  | 3.2                        | 3.2 |
|           |      |                 | 1         | 15             | 184.0                  | 35.8                       | 2.7 |
|           |      |                 | 2.5       | 17             | 184.9                  | 45.0                       | 2.6 |
|           |      |                 | 5         | 12             | 181.3                  | 52.7                       | 3.1 |
|           |      |                 | 10        | 14             | 182.2                  | 49.7                       | 2.8 |
|           |      |                 | 20        | 18             | 185.8                  | 58.2                       | 2.5 |
|           |      |                 | 40        | 13             | 181.0                  | 66.0                       | 2.9 |
| 26        | 2007 | 6               | 10        | 183            | 157                    | 44.7                       | 1.3 |
|           |      |                 | 20        | 171            | 153                    | 49.5                       | 1.3 |
| NP        | 2007 | 8               | 5         | 82             | 168.7                  | 42.3                       | 1.8 |
|           |      |                 | 10        | 82             | 180.3                  | 48.2                       | 1.7 |
| NP        | 2008 | 8               | 5         | 85             | 157.7                  | 44                         | 1.7 |
|           |      |                 | 10        | 91             | 163.8                  | 47.4                       | 1.7 |

SE, standard error. Dose=0, placebo. NP, not published.

### Table 3. Summary of one dose trials for model validation.

| Reference | Race  | Year | Duration (week) | No of patients | Dose (mg) | LDL-C baseline (mg/dL) | Reductions in LDL-C (%) |
|-----------|-------|------|-----------------|----------------|-----------|------------------------|-------------------------|
| 27        | Western | 2004 | 4               | 12             | 10        | 167.6                  | 45.4                    |
| 28        | Western | 2004 | 12              | 627            | 10        | 173.7                  | 46.92                   |
| 29        | Western | 2004 | 6               | 153            | 40        | 257                    | 52.2                    |
| 30        | Western | 2005 | 16              | 521            | 10        | 164.9                  | 47.5                    |
| 31        | Western | 2005 | 12              | 358            | 10        | 171                    | 40.9                    |
| 32        | Western | 2005 | 12              | 482            | 10        | 178.4                  | 45.6                    |
| 33        | Western | 2007 | 8               | 428            | 40        | 189.3                  | 55.9                    |
| 34        | Western | 2007 | 6               | 230            | 40        | 191                    | 57                      |
| 35        | Western | 2007 | 6               | 152            | 40        | 194                    | 54                      |
| 36        | Western | 2008 | 24              | 17             | 10        | 254                    | 47                      |
| 37        | Western | 2008 | 4               | 25             | 40        | 137.8                  | 60                      |
| 38        | Western | 2008 | 8               | 240            | 10        | 131                    | 51                      |
| 39        | Western | 2007 | 12              | 1230           | 40        | 216                    | 54                      |
| 40        | Western | 2008 | 12              | 252            | 10        | 188                    | 42.9                    |
| 41        | Western | 2008 | 48              | 13             | 5         | 153.6                  | 38.2                    |
| 42        | Western | 2008 | 6               | 498            | 10        | 189.2                  | 46.5                    |
| 43        | Western | 2008 | 48              | 52             | 10        | >200                   | 44.32                   |
| 44        | Western | 2009 | 4               | 32             | 10        | 206.7                  | 37                      |
| 45        | Asian  | 2004 | 6               | 23             | 10        | 177.5                  | 43.4                    |
| 46        | Asian  | 2006 | 8               | 40             | 40        | 181.73                 | 48.22                   |
| 47        | Asian  | 2007 | 12              | 515            | 10        | 166.8                  | 47.5                    |
| 48        | Asian  | 2009 | 12              | 35             | 10        | 157.25                 | 47.5                    |
Because the mean percentage change in LDL-C from baseline is generally accepted as the primary efficacy endpoint for lipid-lowering drugs, the PPD analysis in this study focused on the relationship between dose and LDL-C reduction (%). The final model in this study successfully provided the pharmacodynamic profile of rosuvastatin in Western and Asian patients. The rosuvastatin-induced reductions in LDL-C were best described by the simple $E_{\text{max}}$ model fixing $E_0$ at -0.802.

Race was found to affect the parameter $ED_{50}$ and has a value of 1 for Westerners and 0.564 for Asians. No other significant covariate was found. This finding showed that the $ED_{50}$ was approximately twofold higher in Western patients compared with Asian patients. The result was consistent with the reported race difference in rosuvastatin pharmacokinetics: the AUC$^{0–t}$ values were 2.31-, 1.91-, and 1.63-fold higher and the $C_{\text{max}}$ values were 2.36-, 2.00-, and 1.68-fold higher in Chinese, Malay, and Asian Indian subjects, respectively, compared with white subjects[13]. The pharmacodynamics of rosuvastatin with a common $E_{\text{max}}$ and a different $ED_{50}$ for Westerners and Asians confirmed that there is no significant difference between these two populations in the exposure-response relationship for LDL-C reduction. It supports the current dosing recommendation for Westerners (10 to 40 mg) and Asians (5 to 20 mg) that was based on pharmacokinetic exposure[12]. Although the dose in Asians is half that in Westerners, the LDL-C reductions (%) are similar in the two populations. In other words, the two populations exhibit no difference in the LDL-C-lowering effect of rosuvastatin. The findings of this study imply that for a new compound with a similar mechanism of action as rosuvastatin, its efficacy (LDL-C-lowering effect) in Western populations plus its pharmacokinetics in bridging studies[49, 50] in Asian populations may be used to support a registration of the new compound in Asian countries, or vice versa. This will avoid unnecessary duplication of efficacy trials in different races, reduce the cost of drug development, and minimize the exposure of patients to doses with uncertain safety and

| Parameters | TVP | SE  | RSE (%) | 95% CI  |
|------------|-----|-----|---------|---------|
| $E_{\text{max}}$ (%) | 57.0 | 2.2  | 3.86    | 52.7, 61.3 |
| $ED_{50}$ (mg)    | 1.74 | 0.38 | 21.8    | 1.00, 2.48 |
| $E_0$ (%)        | -0.802 |
| $\theta$ (race on $ED_{50}$) | 0.564 | 0.161  | 28.55 | 0.248, 0.880 |
| Inter-trial variability | 3.0 |
| Residual error (SD) | 3.1 |

TVP, typical population parameter value. SE, standard error. RSE, relative standard error, calculated as SE/TVP and expressed as a percentage. 95% CI, lower and upper limits of the 95% confidence interval, calculated as parameter estimates ±1.96 SE. Inter-trials variability was calculated by taking the square root of $\eta$. Residual error was expressed as standard deviation. $\gamma$ was fixed at 1 and $E_0$ was presumed to be -0.802% based on the literature value.

| Parameters | Final estimates | Results of bootstrap simulations | Bootstrap mean/final estimate ratio (%) |
|------------|----------------|----------------------------------|--------------------------------------|
| $E_{\text{max}}$ (%) | 57.0 | 57.2 | 54.8, 59.6 | 100.4 |
| $ED_{50}$ (mg) | 1.74 | 1.79 | 1.22, 2.37 | 102.9 |
| $\theta$ (Race on $ED_{50}$) | 0.564 | 0.600 | 0.334, 0.866 | 106.4 |

TVP, typical population parameter value. SE, standard error. RSE, relative standard error, calculated as SE/TVP and expressed as a percentage. 95% CI, lower and upper limits of the 95% confidence interval, calculated as parameter estimates ±1.96 SE. Inter-trials variability was calculated by taking the square root of $\eta$. Residual error was expressed as standard deviation. $\gamma$ was fixed at 1 and $E_0$ was presumed to be -0.802% based on the literature value.

---

**Table 4.** Final population pharmacodynamic parameter estimates of rosuvastatin.

**Table 5.** Summary of bootstrap validation on the present population pharmacodynamic model.

---

**Figure 2.** The fits through the observed effects with the parameters obtained from the final model. ●, the observed effects in Western patients; ○, the observed effects in Asian patients. The solid curve is the model-predicted dose-response curve in Western patients and the dashed curve is the model-predicted dose-response curve in Asian patients.

**Figure 3.** The dose-response logarithmic curve of rosuvastatin in Western and Asian hypercholesterolemic patients. The solid line, LDL-C% change in Western patients; the dashed line, LDL-C% change in Asian patients.
Figure 4. The goodness-of-fit plots for the final PPD model. (A) Scatter plot of population model-predicted effects (PRED) versus observed effects (OBS). (B) Scatter plot individual model-predicted effects (IPRED) versus OBS. The solid line is a linear regression line and the dashed line is unity. (C) Plot of weighted residuals (WRES) versus PRED. (D) Plot of WRES versus the trials’ identification number (ID).

Figure 5. The values of $E_{\text{max}}$, $ED_{50}$, and $\theta$ (race on $ED_{50}$) in the full data set (●) and for 14 different subsets (○). The solid and dashed lines are the parameter value and ±SE values from the full data set, respectively.

Figure 6. The visual predictive check for the final PPD model in Westerns (left) and Asians (right). The dots are the mean values of LDL-C reduction (%) from the one dose trials. The population-predicted profile (50th percentile) estimated from 1000 Monte Carlo simulations is shown by the solid line, and the 95% prediction intervals are encompassed by the dashed lines in each plot.
efficacy.

Because of the limited amount of data (46 effect samples) available for this study, a previously reported sigmoidal $E_{\text{max}}$ model was not suitable for estimating the four required parameters. Therefore, a simple $E_{\text{max}}$ model was used and the values of $E_{\text{max}}$, $E_D$, $E_0$, and $\theta$ were 55.5%, 1.84 mg, 1.21%, and 0.571. In that case, however, the RSE for the estimated $E_0$ was greater than 900%. To reduce the RSE, $E_0$ was fixed based on literature values. In fact, the estimated values of $E_{\text{max}}$, $E_D$, and $\theta$ (race on $E_0$) were not affected by fixing $E_0$. Consequently, the final model, a simple $E_{\text{max}}$ model with a fixed $E_0$ (-0.812%), was successfully used to describe rosuvastatin pharmacodynamics. Moreover, the robustness of the final model was evaluated by the nonparametric bootstrap and the data-splitting methods, which indicated that selected combinations of data yielded results very similar to those obtained using the original full data set. The predictive performance of the final model was confirmed by the visual predictive check using Monte Carlo simulations, which showed that the mean values of LDL-C reduction (%) from the one-dose trials were mostly distributed within the 5th- to 95th-percentile boundaries of the predictive dose-response profiles for both Westerners and Asians.

It has been reported that the maximum response is usually obtained within 2–4 weeks and is maintained during chronic therapy for a fixed dose of rosuvastatin. For this reason, only the mean values of LDL-C reduction (%) that were observed at least 4 weeks after administration were used in the model development. Therefore, it should be noted that the final model in this study was developed to describe the steady state for the LDL-C-lowering effect of rosuvastatin.

In conclusion, the race difference in the pharmacodynamics of rosuvastatin is consistent with that in the pharmacokinetics of the drug, which confirms that there is no significant difference in the exposure-response relationship for LDL-C reduction between Asians and Westerners. This study suggests that for a new compound with a mechanism of action similar to that of rosuvastatin, its efficacy in Western populations plus its pharmacokinetics in bridging studies in Asian populations may be used to support a registration of the new compound in Asian countries.

Acknowledgements

We thank Dr Ya-ning WANG (US FDA) for valuable discussions and advice. This study was supported by the National Science and Technology Supporting Projects of China (2008BA151B03, 2009ZX09502-021), E-Institute of Shanghai High Education (E03008), the Leading Academic Discipline Project of the Shanghai Municipal Education Commission (J50303, 2008GSP19-5), and the Special Fund of Scientific Research for Selecting and Training Outstanding Young Teachers of Shanghai Municipal Education (SZY07027).

Author contribution

Juan YANG and Qing-shan ZHENG conceived and designed the study. Juan YANG, Ying-chun HE, and Yu-cheng SHENG performed the electronic literature retrieval and data extraction. Juan YANG, Lu-jin LI, Kun WANG, and Ling XU analyzed the data. Xiao-hui HUANG and Feng GUO discussed the results. Juan YANG and Qing-shan ZHENG wrote the paper. All authors checked the final manuscript before submission.

References

1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504–8.
2. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383–90.
3. Olsson AG, Istad H, Lurulia O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin compared over 52 weeks for treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044–51.
4. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62: 2075–85.
5. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
6. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003; 91: 20–23C.
7. McGauff G, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B–32B.
8. Leonard KA. Treatment and prevention of dyslipidemia with rosuvastatin (Crestor). Nurse Pract 2004; 29: 11–5.
9. Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003; 25: 2215–24.
10. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; 42: 1116–21.
11. Tseng TG, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin 2008; 24: 2575–85.
12. AstraZeneca Canada Inc. PRODUCT MONOGRAPH. Pr CRESTOR ® rosuvastatin. Tablets, 5, 10, 20, and 40 mg. LIPID METABOLISM REGULATOR [monograph on the Internet]. 2008 [cited 2009 May 7]. Available from: http://www.astrazeneca.ca/documents/ProductPortfolio/CRESTOR_PM_en.pdf.
13. Lee E, Ryan S, Birmingham B, Zaliowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78: 330–41.
14. Saito Y, Goto Y, Dane A, Strutt K, Raza A. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003; 10: 329–36.
Arkema R, et al. Model-based development of gemcabene, a new lipid-altering agent. APAS J 2005; 7: E513–22.
16 Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic—pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511–28.
17 Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California, San Francisco, CA. 1989.
18 Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486–95
19 Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003; 56: 205–13.
20 Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, et al. Comparison of effects of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIA or IIB hypercholesterolemia. Am J Cardiol 2002; 89: 268–75.
21 Brown WV, Bays HE, Hassman DR, McPherson R, Chitra RR, et al. Efficacy and safety of rosuvastatin compared with Pravastatin and Simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002; 144: 1036–43.
22 Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of Rosuvastatin and Atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003; 91: 33–41.
23 Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J 2004; 148: e4.
24 Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006; 22: 2041–53.
25 Yamamoto A, Arakawa K, Sasaki J, Matsuzaka Y, Takemura K, Yamamoto A, et al. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. J Atheroscler Thromb 2002; 9: 48–56.
26 Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 2007; 99: 1538–43.
27 Kosoglou T, Statkevich P, Yang B, Boutros T, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004; 20: 1185–95.
28 Strandberg TE, Feely J, Sigurdsson EL: DISCOVERY study group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004; 26: 1821–33.
29 Ballantyne CM, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther 2004; 26: 1855–64.
30 Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol 2005; 100: 309–16.
31 Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, et al. The DISCOVERY PENTA study: a Direct Static Comparison of LDL-C Value — an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 2005; 21: 1307–15.
32 Bots AF, Kastelein JJ; Discovery Netherlands Investigators. Achieving lipid goals in real life: the Dutch DISCOVERY study. J Int J Clin Pract 2005; 59: 1387–94.
33 Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194: e154–64.
34 Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673–80.
35 Asztalos BF, Le Mauf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007; 99: 681–5.
36 Talini E, Di Bello V, Bianchi C, Palagi C, Delle Donne MG, Penno G, et al. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin: a preliminary echocardiographic study. Atherosclerosis 2008; 197: 346–54.
37 Sviridov D, Hoang A, Oei E, Watts G, Barrett PH, Nestel P. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 2008; 197: 732–9.
38 Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007; 100: 1245–8.
39 Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol 2007; 100: 1387–96.
40 Laks T, Keba E, Leiner M, Merilind E, Petersen M, Reinmerts S, et al. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study. Vasc Health Risk Manag 2008; 4: 1407–16.
41 Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008; 155: 584.e1–8.
42 Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 2008; 111: 219–28.
43 Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Zanatta N, Mazzarella B, et al. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Am J Cardiovasc Drugs 2008; 8: 265–70.
44 Pirro M, Schillaci G, Romagno PF, Mannarino MR, Bagaglia F, Razzi R, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther 2009; 14: 14–21.
45 Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 157–61.
46 Wongwaiwanthanukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann Pharmacother 2006; 40: 1917–23.
47 Zhu JR, Tomlinson B, Ro YM, Sim KH, Lee YT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 2007; 23: 3055–68.

48 Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009; 26: 958–64.

49 Liu JP, Chow SC. Bridging studies in clinical development. J Biopharm Stat 2002; 12: 359–67.

50 Uyama Y, Shibata T, Nagai N, Hanaoka H, Toyoshima S, Mori K. Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin Pharmacol Ther 2005; 78: 102–13.

51 Othman AA, Tenero DM, Boyle DA, Eddington ND, Fossler MJ. Population pharmacokinetics of S (-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J 2007; 9: E208–18.

52 Wu KH, Cui YM, Guo JF, Zhou Y, Zhai SD, Cui FD, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 2005; 33: 1268–75.